SOAT1 and COVID-19: For example, anti–IL-6(R) antibodies, IL-1 receptor antagonists, and JAK/STAT inhibitors are currently undergoing clinical testing in patients with COVID-19 (27–32) and carry the potential to further compromise the patient’s ability to eradicate the virus.